[Skip to Navigation]
Research Letter
August 31, 2020

Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder

Author Affiliations
  • 1Department of Neurology, Mayo Clinic, Jacksonville, Florida
  • 2Department of Neurology, Mayo Clinic, Rochester, Minnesota
  • 3Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • 4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
JAMA Neurol. 2020;77(12):1575-1577. doi:10.1001/jamaneurol.2020.3115

Data on long-term outcomes of patients with myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disorder (MOGAD) are scarce.1,2 We report outcomes in a single-institution cohort with long-term follow-up.

We retrospectively identified 11 adult and 18 pediatric (onset age younger than 18 years) Mayo Clinic patients from January 1, 2000, through May 31, 2019, with (1) MOGAD clinical phenotype3; (2) MOG-IgG 1 seropositivity (median titer, 1:100; range, 1:20-1:1000; 8 of 13 serial samples persistently positive)3; and (3) 9 or more years’ follow-up from onset. The study was approved by the Mayo Foundation Institutional Review Board (IRB No. 08.006647). Written informed consent was provided by patients or parents.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×